Literature DB >> 8486944

Prevention of group B streptococcal colonization and bacteremia in neonatal mice with topical vaginal inhibitors.

F Cox1, L Taylor, E K Eskew, S J Mattingly.   

Abstract

Pregnant Swiss-Webster mice were vaginally inoculated with 10(5) virulent and avirulent serotype III Streptococcus agalactiae and treated 4 days later with topical vaginal inhibitor solutions. Preparations containing lipoteichoic acid (LTA) or glycerophosphate (GP), the repeating linear backbone of LTA, significantly reduced neonatal colonization and bacteremia by the virulent isolate and colonization by the avirulent strain. Similar results were obtained if bacteria were preincubated with LTA or GP at 37 degrees C for 30 min before vaginal inoculation. Human serum albumin (HSA), a known inhibitor of binding of LTA to human fetal epithelial cells, also resulted in reduction in colonization and bacteremia of neonatal mice. However, maternal treatment with a combination of HSA (2%) and GP (1%) completely prevented neonatal colonization and bacteremia without altering the normal aerobic bacterial vaginal flora. These results provide impetus to the development of an alternative means of preventing neonatal group B streptococcal infections in humans without requiring maternal immunization or chemoprophylaxis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486944     DOI: 10.1093/infdis/167.5.1118

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization.

Authors:  Kathryn A Patras; Nai-Yu Wang; Erin M Fletcher; Courtney K Cavaco; Alyssa Jimenez; Mansi Garg; Joshua Fierer; Tamsin R Sheen; Lakshmi Rajagopal; Kelly S Doran
Journal:  Cell Microbiol       Date:  2013-01-30       Impact factor: 3.715

2.  Lipoteichoic acid fractions from pathogenic and apathogenic Listeria species and Staphylococcus aureus induce similar amounts of macrophage-derived cytokines.

Authors:  T Nichterlein; M Kretschmar; G J Ruhland; F Fiedler; H Hof
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

Review 3.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

4.  Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models.

Authors:  Emiliano Chiarot; Angela Spagnuolo; Silvia Maccari; Eleonora Naimo; Alessandra Acquaviva; Raffaella Cecchi; Bruno Galletti; Monica Fabbrini; Elena Mori; Paolo Ruggiero; Guido Grandi; Maria Rita Fontana; Giuliano Bensi; Immaculada Margarit
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.